Mechanisms of anticancer agents

Active Research Project
Benedict Law, Ph.D.
Last Updated: 
June 14, 2022

To improve treatment outcome, multiple drugs of distinctive mechanisms but complementary anticancer activities are often used to enhance antitumor efficacy and minimize risk of acquiring drug resistance. Specifically, the Law lab investigates the synergistic effects of drug combinations, with the aim of developing new therapeutic strategies, such as drug-induced targeting approaches, for cancer treatments. In addition, the lab is actively involved in studying other anticancer agents, including a mitochondrial disrupting peptide to induce the apoptosis of cancer cells, CXCR4-targeting delivery, anti-receptor for advanced glycation end products (RAGE) and Herceptin antibodies for immunotherapy, and docosahexaenoic acid as a sensitizer.

List of Publications:

(1) Bellat, V., et al., Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor beta, BMC Cancer, 20(1):661: 2020.  

(2) Lee, H.H., et al., Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer, PLoS One12(2):e0171044: 2017. 

(3) Meghnani V., et al., The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors,Int. J. Biochem. Cell Biol., 57:54-62: Dec. 2014.

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065